Comment
Author: Admin | 2025-04-28
HomeVraylarGeneric Availability Last updated on Jan 8, 2025.Vraylar is a brand name of cariprazine, approved by the FDA in the following formulation(s):VRAYLAR (cariprazine hydrochloride - capsule;oral) Manufacturer: ABBVIE Approval date: September 17, 2015 Strength(s): EQ 1.5MG BASE [RLD], EQ 3MG BASE [RLD], EQ 4.5MG BASE [RLD], EQ 6MG BASE [RLD] Has a generic version of Vraylar been approved?No. There is currently no therapeutically equivalent version of Vraylar available in the United States.Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vraylar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.See also: Generic Drug FAQ.Related patentsPatents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims. Patent 7,737,142Patent expiration dates: September 17, 2029✓ Patent use: TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE✓ Drug substance✓ Drug product September 17, 2029✓ Patent use: TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) WITH CARIPRAZINE✓ Drug substance✓ Drug product September 17, 2029✓ Patent use: TREATMENT OF SCHIZOPHRENIA WITH CARIPRAZINE✓ Drug substance✓ Drug product September 17, 2029✓ Patent use: TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE✓ Drug substance✓ Drug product September 17, 2029✓ Patent use: ADJUNCTIVE THERAPY TO ANTIDEPRESSANTS FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER✓ Drug substance✓ Drug product Patent 7,943,621Patent expiration dates: December 16, 2028✓ Drug substance✓ Drug product Pharmaceutical formulations containing dopamine receptor ligandsPatent RE47350Issued: April 16, 2019Inventor(s): Sarkar Ranajoy & Dedhiya Mahendra G. & Chhettry AnilAssignee(s): Richter Gedeon Nyrt.The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.Patent expiration dates: July 16, 2029✓ Patent use: TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE July 16, 2029✓ Patent use: TREATMENT OF SCHIZOPHRENIA WITH CARIPRAZINE July 16, 2029✓ Patent use: ADJUNCTIVE THERAPY TO ANTIDEPRESSANTS FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER July 16, 2029✓ Patent use: TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE July 16, 2029✓ Patent use: TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) WITH CARIPRAZINE Patent RE49110Patent expiration dates: July 16, 2029✓ Patent use: TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) WITH CARIPRAZINE July 16, 2029✓ Patent use: TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE July 16, 2029✓ Patent use: TREATMENT OF SCHIZOPHRENIA WITH CARIPRAZINE July 16, 2029✓ Patent use: ADJUNCTIVE THERAPY TO ANTIDEPRESSANTS FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER Patent RE49302Patent expiration dates: July 16, 2029✓ Patent use: TREATMENT OF SCHIZOPHRENIA WITH CARIPRAZINE July 16, 2029✓ Patent use: ADJUNCTIVE THERAPY TO ANTIDEPRESSANTS
Add Comment